Combining Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Effects and Mechanisms of Indirubin on Acute Lymphoblastic Leukemia
Drug Design, Development and Therapy · 2025-02 · Volume 19 · 1083-1103
DOI: 10.2147/dddt.s500249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-02. Verfasst von Lu Jin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Network Pharmacology, Indoles, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
To investigate the effects and underlying mechanisms of indirubin in treating ALL using network pharmacology and experimental validation.
Methods
Potential targets of indirubin- and ALL-related genes were identified using public databases. Core genes were filtered through protein-protein interaction analysis in Cytoscape. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted to explore the potential mechanisms of indirubin against ALL. Drug-disease-functional annotation-signaling pathway network maps were constructed. Molecular docking between indirubin and core proteins was performed using AutoDock Vina software. Finally, both in vitro and in vivo experiments were performed to validate these findings.
Results
PPI network analysis identified eight potential core targets of indirubin in ALL: AKT1, CASP3, and the mammalian target of rapamycin. GO and KEGG enrichment analyses suggested that the mechanism of action of indirubin against ALL involves multiple biological functions and signaling pathways, with the PI3K-AKT pathway likely playing a central role. Molecular docking findings further confirmed the strong binding affinity of indirubin for the core targets. Both in vitro and in vivo experiments demonstrated that indirubin inhibited ALL cell proliferation and induced cell cycle arrest and apoptosis; the underlying mechanism may involve the PI3K-AKT signaling pathway.
Conclusion
The action and mechanism of indirubin in ALL through network pharmacology, as well as in vivo and in vitro experimental validation were elucidated, offering new insights and potential therapeutic avenues for the treatment of ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
- Department of Pediatric Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
- Department of Immunology, College of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
- Department of Central Laboratory, Guizhou Provincial People's Hospital, Guiyang, Guizhou, People's Republic of China.
- Tissue Engineering and Stem Cell Experiment Center, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Zitieren
APA
Jin, L., Guan, Y., Li, X., Wang, M., Shen, Y., Wang, N., & He, Z. (2025). Combining Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Effects and Mechanisms of Indirubin on Acute Lymphoblastic Leukemia. Drug Design, Development and Therapy, Volume 19, 1083-1103. https://doi.org/10.2147/dddt.s500249
Vancouver
Jin L, Guan Y, Li X, Wang M, Shen Y, Wang N, et al. Combining Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Effects and Mechanisms of Indirubin on Acute Lymphoblastic Leukemia. Drug Design, Development and Therapy. 2025;Volume 19:1083-1103. doi:10.2147/dddt.s500249
BibTeX
@article{Jin2025,
author = {Jin, Lu and Guan, Yunshuang and Li, Xue and Wang, Mingyue and Shen, Ying and Wang, Nianxue and He, Zhixu},
title = {Combining Network Pharmacology, Molecular Docking and Experimental Validation to Explore the Effects and Mechanisms of Indirubin on Acute Lymphoblastic Leukemia},
journal = {Drug Design, Development and Therapy},
year = {2025},
volume = {Volume 19},
pages = {1083--1103},
doi = {10.2147/dddt.s500249}
}
EUVIMED